A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
Eitan Neidich, Alon B. Neidich, David A. Axelrod, MD, and John P. Roberts, MD
Geographic disparities in availability of organs for transplant have spawned for-profit companies that help patients get on waitlists in more than one region and arrange travel for them if an organ becomes available.
When identifying underrepresented subgroups deserving of special recruitment efforts for research participation, social determinants of health other than race should be given more consideration.
Bruce C. Vladeck, PhD, Sander Florman, MD, and Jonathan Cooper, JD
The United Network for Organ Sharing’s geographic allocation system is outdated and inequitable, particularly in light of improved ability to transport organs. Allocation should be based on common medical criteria, not accidents of geography.
Daphne C. Ferrer, MD and Peter M. Yellowlees, MBBS, MD
Telepsychiatry extends access to psychiatric treatment to those who might not otherwise get it, but licensure problems and the risk of boundary violations between patients and physicians need to be worked out.
Amy B. Cadwallader, PhD, Kavitha Nallathambi, MPH, MBA, and Carly Ching, PhD
Poor-quality antimicrobial medicines continue to proliferate across supply chains, threatening patients’ health and safety, especially in low- and middle-income regions.
AMA J Ethics. 2024;26(6):E472-478. doi:
10.1001/amajethics.2024.472.